

MERRIMACK PHARMACEUTICALS INC

Form 3

May 21, 2014

**FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Â Laivins Peter N

(Last)

(First)

(Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)

05/14/2014

3. Issuer Name and Ticker or Trading Symbol

MERRIMACK PHARMACEUTICALS INC [MACK]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other

(give title below) (specify below)

SVP of Development

6. Individual or Joint/Group

Filing(Check Applicable Line)

☒ Form filed by One Reporting Person☐ Form filed by More than One Reporting PersonC/O MERRIMACK  
PHARMACEUTICALS,  
INC.,Â ONE KENDALL  
SQUARE, SUITE B7201

(Street)

CAMBRIDGE,Â MAÂ 02139

(City)

(State)

(Zip)

**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Common Stock

2,000

D

Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)3. Title and Amount of  
Securities Underlying  
Derivative Security4. Conversion  
or Exercise5. Ownership  
Form of6. Nature of Indirect  
Beneficial Ownership  
(Instr. 5)

# Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	Â (1)	11/01/2021	Common Stock	40,000	\$ 6.78	D	Â
Stock Option (right to buy)	Â (2)	06/12/2022	Common Stock	10,000	\$ 6.8	D	Â
Stock Option (right to buy)	Â (3)	08/22/2022	Common Stock	22,300	\$ 7.53	D	Â
Stock Option (right to buy)	Â (4)	03/11/2023	Common Stock	35,000	\$ 6.35	D	Â
Stock Option (right to buy)	Â (5)	02/10/2024	Common Stock	100,000	\$ 5.02	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Laivins Peter N C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201 CAMBRIDGE, MA 02139	Â	Â	Â SVP of Development	Â

## Signatures

/s/ Jeffrey A. Munsie,  
attorney-in-fact

05/21/2014

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) This option vested as to 1/6th of the shares on 4/17/12 and vests in equal quarterly installments thereafter until 10/17/14.
- (2) This option vested as to 1/12th of the shares on 9/13/12 and vests in equal quarterly installments thereafter until 6/13/15.
- (3) This option vested as to 1/12th of the shares on 11/23/12 and vests in equal quarterly installments thereafter until 8/23/15.
- (4) This option vested as to 1/12th of the shares on 6/12/13 and vests in equal quarterly installments thereafter until 3/12/16.
- (5) This option vested as to 1/12th of the shares on 5/11/14 and vests in equal quarterly installments thereafter until 2/11/17.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.